|
BREAST
CANCER HER 2 +
|
|
Setting
|
Trial
|
Status
|
Network
|
|
1st
Line Metastatic
|
GSK
EGF 108919 Taxane + Herceptin vs. Taxane + Lapatinib
|
OPEN
|
Suburban
|
|
ADJUVANT
|
CIRG/TRIO (011BETH)TCH/AVASTIN
vs TCH
|
OPEN
|
TORI
|
|
HER2-
|
|
ADJUVANT
|
TITAN- AC/Taxol vs AC/Ixempra
for triple negative breast cancer
|
OPEN
|
Suburban
|
|
ADJUVANT
|
ROCHE TC/ TAC/TOE (Avastin
arm)
|
OPEN
|
TORI
|
|
1st,
2nd, 3rd Line metastatic breast cancer triple negative
|
BiPar EAP-Gemzar/Carbo + parp
inhibitor (BSI-201)
|
OPEN
|
TORI
|
|
1st
Line metastatic
|
TRIO 018 Letrozole + or PD
0332991 (oral CDK inhibitor) for ER +, HER2 metastatic breast cancer in
post menopausal women
|
OPEN
|
TORI
|
|
Refractory
breast
|
Novartis TK12202 Open label
TK1258 in FGFR amplified and non amplified metastatic HER2 breast cancer
|
OPEN
|
TORI
|
|
1st
Line Metastatic Registry
|
VIRGO Observational study of
treatment for 1st line or locally recurrent
|
OPEN
|
Suburban
|
|
1st
Line Metastatic non treatment
|
Best Rx Metastatic breast
block collection
|
OPEN
|
TORI
|
|
|
|
|
|
HER-2 + OR -
|
|
Neoadjuvant
|
ORegan
trial: Taxotere + Xeloda sequentially or concomitantly
|
OPEN
|
Suburban
|
|
Metastatic
|
Zometa
q 4 wk vs. q 12 wk vs. placebo after treatment with Zometa for at least 9
12 months NO UPPER LIMIT ON DOSES
|
OPEN
|
Suburban
|
|
|
|
COLON/GI
CANCER
|
|
2nd
Line metastatic
|
Amgen 20060141.FOLFIRI +
Avastin vs. FOLFIRI + Panitumumab
|
OPEN
|
TORI
|
|
Refractory
colon
|
Perifosine 343 Xeloda = or
Perifosine (oral AKT inhibitor)
|
OPEN
|
Suburban
|
|
2nd
or 3rd Line Esophageal/Gastric
|
TORI GI-06 Rad 001 (mTOR
inhibitor)
|
OPEN
|
TORI
|
|
Adjuvant
pancreatic
|
TORI PA-01 Gemzar + Dasatinib
vs. Gemzar alone
|
OPEN
|
TORI
|
|
|
|
LUNG/NSCLC
|
|
1st
Line metastatic adenocarcinoma
or squamous
|
Acorn AC01L08 Erbitux + platinum
based chemo
|
OPEN
|
Suburban
|
|
1st
Line metastatic non-squamous
lung cancer
|
JMHD Taxol/Carbo/Bev vs.
Alimta/Carbo/ Bev
|
OPEN
|
Suburban
|
|
1st Line metastatic
squamous NSCLC
|
LUN 201 Carbo/Gemzar + or
BSI-201 (parp inhibitor)
|
OPEN
|
Suburban
|
|
2nd
Line
|
BI 1199.14 Alimta +
BIBF1120 (small molecule TKI)
|
OPEN
|
Suburban
|
|
2nd
Line
|
CASA Taxotere + or ASA404
(T-VDA)
|
OPEN
|
TORI
|
|
2nd,
3rd Line
|
LUN 200 Erlotonib +
Pazopanib/Placebo
|
OPEN
|
Suburban
|
|
|
|
OTHER
STUDIES
|
|
GIST
|
Registry Gastrointestinal Stromal
Tumors registry
|
OPEN
|
Suburban
|
|
Prostate
|
BMS CA180227 Taxotere + or Dasatinib
for castration resistant prostate cancer
|
OPEN
|
Suburban
|
|
Prostate 2nd or 3rd
line
|
BMS
CA 184-043 Ipilimumab immunotherapy/ placebo
|
OPEN
|
Suburban
|
